Ben Peloton's questions to CMRX leadership • Q1 2024
Question
Asked about the future development strategy for ONC206, specifically whether it would be pursued as a monotherapy or combination therapy, and if it would target CNS or non-CNS tumors.
Answer
The company is prioritizing monotherapy development for ONC206. The focus is on solid tumors, both within and outside the CNS, guided by preclinical data and specific biomarkers to identify the most promising indications for an efficient path to approval.